386 related articles for article (PubMed ID: 26378648)
1. Pharmacotherapy for Nonalcoholic Fatty Liver Disease.
Gawrieh S; Chalasani N
Semin Liver Dis; 2015 Aug; 35(3):338-48. PubMed ID: 26378648
[TBL] [Abstract][Full Text] [Related]
2. Novel Pharmacotherapy Options for NASH.
Ratziu V
Dig Dis Sci; 2016 May; 61(5):1398-405. PubMed ID: 27003143
[TBL] [Abstract][Full Text] [Related]
3. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
4. NASH: A glance at the landscape of pharmacological treatment.
Brodosi L; Marchignoli F; Petroni ML; Marchesini G
Ann Hepatol; 2016; 15(5):673-81. PubMed ID: 27493105
[TBL] [Abstract][Full Text] [Related]
5. Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway.
Filozof C; Goldstein BJ; Williams RN; Sanyal A
Drugs; 2015 Aug; 75(12):1373-92. PubMed ID: 26201461
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic fatty liver disease: new treatments.
Hardy T; Anstee QM; Day CP
Curr Opin Gastroenterol; 2015 May; 31(3):175-83. PubMed ID: 25774446
[TBL] [Abstract][Full Text] [Related]
7. Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.
Imprialos K; Stavropoulos K; Bouloukou S; Kerpiniotis G; Karagiannis A; Doumas M
Curr Vasc Pharmacol; 2018; 16(3):276-288. PubMed ID: 28676020
[TBL] [Abstract][Full Text] [Related]
8. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
[TBL] [Abstract][Full Text] [Related]
9. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
Mahjoubin-Tehran M; De Vincentis A; Mikhailidis DP; Atkin SL; Mantzoros CS; Jamialahmadi T; Sahebkar A
Mol Metab; 2021 Aug; 50():101049. PubMed ID: 32673798
[TBL] [Abstract][Full Text] [Related]
10. Treatment options for nonalcoholic steatohepatitis - a safety evaluation.
Issa D; Wattacheril J; Sanyal AJ
Expert Opin Drug Saf; 2017 Aug; 16(8):903-913. PubMed ID: 28641031
[TBL] [Abstract][Full Text] [Related]
11. Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.
Loomba R; Sanyal AJ; Kowdley KV; Terrault N; Chalasani NP; Abdelmalek MF; McCullough AJ; Shringarpure R; Ferguson B; Lee L; Chen J; Liberman A; Shapiro D; Neuschwander-Tetri BA
Gastroenterology; 2019 Jan; 156(1):88-95.e5. PubMed ID: 30222962
[TBL] [Abstract][Full Text] [Related]
12. Current and emerging pharmacological therapy for non-alcoholic fatty liver disease.
Eshraghian A
World J Gastroenterol; 2017 Nov; 23(42):7495-7504. PubMed ID: 29204050
[TBL] [Abstract][Full Text] [Related]
13. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
Corey KE; Rinella ME
Dig Dis Sci; 2016 May; 61(5):1387-97. PubMed ID: 26942734
[TBL] [Abstract][Full Text] [Related]
14. Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis.
Wree A; Mehal WZ; Feldstein AE
Semin Liver Dis; 2016 Feb; 36(1):27-36. PubMed ID: 26870930
[TBL] [Abstract][Full Text] [Related]
15. Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis.
Venetsanaki V; Karabouta Z; Polyzos SA
Eur J Pharmacol; 2019 Nov; 863():172661. PubMed ID: 31536725
[TBL] [Abstract][Full Text] [Related]
16. [New pharmacological treatment options for nonalcoholic fatty liver disease].
Stefan N
Internist (Berl); 2020 Jul; 61(7):759-765. PubMed ID: 32409850
[TBL] [Abstract][Full Text] [Related]
17. Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis.
Musso G; Cassader M; Paschetta E; Gambino R
Gastroenterology; 2018 Aug; 155(2):282-302.e8. PubMed ID: 29906416
[TBL] [Abstract][Full Text] [Related]
18. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes.
Ahmed A; Wong RJ; Harrison SA
Clin Gastroenterol Hepatol; 2015 Nov; 13(12):2062-70. PubMed ID: 26226097
[TBL] [Abstract][Full Text] [Related]
19. Obeticholic acid for the treatment of nonalcoholic steatohepatitis.
Shah RA; Kowdley KV
Expert Rev Gastroenterol Hepatol; 2020 May; 14(5):311-321. PubMed ID: 32241197
[TBL] [Abstract][Full Text] [Related]
20. NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges.
Alkhouri N
Expert Opin Investig Drugs; 2020 Feb; 29(2):87. PubMed ID: 31984804
[No Abstract] [Full Text] [Related]
[Next] [New Search]
